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p62/SQSTM1 enhances breast cancer stem-like properties
by stabilizing MYC mRNA
L-Z Xu1,2,8, S-S Li1,2,8, W Zhou1,2, Z-J Kang1,2, Q-X Zhang3, M Kamran1,2, J Xu1,2, D-P Liang1,2, C-L Wang1,2, Z-J Hou1,2, X-B Wan4,
H-J Wang5, EW-F Lam6, Z-W Zhao7 and Q Liu1,2
Aberrant p62 overexpression has been implicated in breast cancer development. Here, we found that p62 expression was elevated
in breast cancer stem cells (BCSCs), including CD44+CD24− fractions, mammospheres, ALDH1+ populations and side population cells.
Indeed, short-hairpin RNA (shRNA)-mediated knockdown of p62 impaired breast cancer cells from self-renewing under anchorage-
independent conditions, whereas ectopic overexpression of p62 enhanced the self-renewal ability of breast cancer cells in vitro.
Genetic depletion of p62 robustly inhibited tumor-initiating frequencies, as well as growth rates of BCSC-derived tumor xenografts in
immunodeﬁcient mice. Consistently, immunohistochemical analysis of clinical breast tumor tissues showed that high p62 expression
levels were linked to poorer clinical outcome. Further gene expression proﬁling analysis revealed that p62 was positively correlated
with MYC expression level, which mediated the function of p62 in promoting breast cancer stem-like properties. MYC mRNA level was
reduced upon p62 deletion by siRNA and increased with p62 overexpression in breast cancer cells, suggesting that p62 positively
regulated MYC mRNA. Interestingly, p62 did not transactivate MYC promoter. Instead, p62 delayed the degradation of MYC mRNA
by repressing the expression of let-7a and let-7b, thus promoting MYC mRNA stabilization at the post-transcriptional level. Consistently,
let-7a and let-7b mimics attenuated p62-mediated MYC mRNA stabilization. Together, these ﬁndings unveiled a previously
unappreciated role of p62 in the regulation of BCSCs, assigning p62 as a promising therapeutic target for breast cancer treatments.
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INTRODUCTION
As a highly heterogeneous malignancy, breast cancer is the
leading cause of female cancer-related deaths.1–3 Although the
mortality rate has drastically dropped as a result of improved
early diagnostic methods and therapeutic advancements,4 a
signiﬁcant portion of patients eventually suffer from tumor
relapse and develop drug resistance. Accumulating evidence
demonstrates that breast cancer stem cells (BCSCs), a tumor
subpopulation which is critical for breast cancer relapse and drug
resistance,4,5 possess indeﬁnite potential for self-renewal that
drives tumorigenesis.6 For example, breast carcinomas with high
ALDH1+ activity are capable of self-renewal and generating
tumors that recapitulate the heterogeneity of the parental
tumor.7 In addition, identiﬁcation and isolation of cancer stem
cells from a variety of malignancies provides a powerful tool to
investigate the tumorigenic process.8–15 Recent studies showed
that genes related to the epithelial-to-mesenchymal process, such
as Slug, Gli-2, ZEB-1 and ZEB-2, are enriched in the CD44+CD24− /low
subpopulation.16 Compared with CD24+ cells, TGF-β signaling
activities, as well as expression of TGF-β1 receptor TGF-BR II, are
elevated in CD44+ cells derived from breast cancer tissues.17 CD44+
CD24− /low subpopulation tumor cells are signiﬁcantly associated
with lymph-node involvement, estrogen receptor and progestogen
receptor status and a shorter cumulative disease-free survival (DFS)
and overall survival (OS).18 Consistently, tumor cells derived from
the CD44+CD24− /lowESA+ subpopulation preferentially survive
chemotherapy.19 CD24− /low/CD44+ BCSCs are also more resistant
to fractionated doses of irradiation, providing explanation for the
accelerated repopulation of tumor cells observed during intervals in
radiotherapy.20 Our recent work has shown that epirubicin-resistant
MCF-7 (EpiR-MCF-7) cells contain a higher percentage of CD44+
CD24− /low subpopulation and abundance of self-renewal gene
expression (for example, CTNNB1, MYC, SOX2, POU5F1 and
NANOG).21 However, due to the high heterogeneity and dynamic
progression of BCSCs, no effective strategies have hitherto been
developed to eliminate BCSCs.
The signaling protein p62 (also termed SQSTM1, ZIP3, A170) is
originally identiﬁed as a cytosolic 62-kDa protein, which can bind
to Src homology 2 (SH2) domain of p56lck.22 Further studies reveal
that p62 contains several important functional domains, which
mediate the cross-talk with a number of signaling molecules to
regulate the activities of downstream effectors, such as NRF2,23
NF-κB24,25 and mTOR.26 Additionally, p62 is required during
autophagic process owing to its ability to bind the ubiquitinated
autophagic substrates through the UBA domain, and the ability to
interact with LC3 through the LIR domain.27 Recent studies indicate
that aberrant p62 overexpression is implicated in numerous cancer
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types,28–32 including breast cancer.33–35 For example, accumulation
of p62 promotes hepatocellular carcinoma development through
NRF2 stabilization, leading to persistent transcriptional activation
of antioxidant target genes, such as Nqo1 and Gstm1.36 5q copy
number gains-driven overexpression of p62 mediates resistance
to redox stress in kidney cancer.32 In breast cancer, p62
is signiﬁcantly correlated with advanced clinical stages as well as
a higher proportion of positive lymph nodes and lymphovascular
invasion.35 High p62 expression is also associated with positive
EGF receptor, HER2, HER3, HER4 and distant metastasis in breast
cancer showing aggressive features.34 These ﬁndings endow p62
with a potential oncogenic role in tumor progression. However,
the detailed mechanisms for p62-mediated breast cancer initiation
and progression, especially a role of p62 in promoting breast
cancer stem-like properties, are still poorly characterized. In this
study, we set out to investigate the potential role of p62 in the
regulation of breast cancer stem-like properties and the mechan-
ism involved.
RESULTS
p62 expression is elevated in BCSC-enriched populations
The CD44+/CD24− subpopulations of normal and cancerous breast
epithelial cells are suggested to display stem-cell properties.8 In an
effort to explore the relationship between p62 and breast cancer
stem-like properties, we ﬁrst analyzed the gene expression patterns
of CD44+/CD24− and CD44−/CD24+ subpopulations of the MCF-10A
breast epithelial cell line with basal cell phenotype (GSE15192 from
the PubMed GEO database).16 As shown in the heat map of
Figure 1A(a), genes that mediated stem-like properties, such as
SOX2, POU5F1 (also known as OCT4) and NANOG, were found to
elevate in the CD44+/CD24− subpopulation. Notably, p62 (also
known as SQSTM1) expression value of the CD44+/CD24− sub-
population was signiﬁcantly higher than that of CD44−/CD24+
subpopulation (Figure 1A(b)).
Next, we conducted mammosphere formation, ALDH1+ and side
population (SP) sorting assays to enrich for BCSCs for subsequent
mRNA and protein expression analysis. SOX2, POU5F1 and NANOG
were employed as markers for stem-like properties of the enriched
populations. Compared with cells grown in monolayer cultures,
spheroids isolated from MDA-MB-231 cells displayed higher
mRNA and protein levels of p62 expression, associated with higher
expression levels of SOX2, POU5F1 and NANOG (Figure 1B). In
addition, spheroids isolated from SUM149 cells showed higher
p62 mRNA expression levels compared with monolayer cells
(Supplementary Figure 1A). ALDH1-positive sorting assay indicated
that ALDH1+ cells also exhibited much higher p62 mRNA and
protein expression levels than ALDH1− cells (Figure 1C). Moreover,
increased p62 mRNA expression was also observed in the SP
compared with the non-SP isolated from MDA-MB-231 cells
(Figure 1D). Together, these observations indicated that p62
was elevated in the BCSC-enriched populations, suggesting that
p62 has a key role in promoting breast cancer stem-like properties.
p62 is an important mediator of stem-like properties for breast
cancer cells in vitro
To assess the contribution of p62 in promoting breast cancer stem-
like properties, we used short-hairpin RNA (shRNA) to mediate p62
suppression in MDA-MB-231 and SUM149 cells with relatively higher
endogenous p62 expression levels, and lentivirus to facilitate
ectopic overexpression of p62 in MCF-7 cells which displayed
lower p62 levels (Supplementary Figure 2). The efﬁciencies of p62
depletion and overexpression were then assessed by western
blotting. As shown in Figure 2A and Supplementary Figure 1B, p62
was effectively depleted by two different shRNAs in MDA-MB-231
and SUM149 cells, and signiﬁcantly induced by lentivirus transduc-
tion in MCF-7 cells.
Next, we performed plate colony formation, mammosphere
formation and ALDH1-positive sorting assays to investigate the
role of p62 in promoting self-renewal abilities, a key characteristic
of BCSCs. The colony numbers (up to 14 days) on regulate plates
were markedly decreased following the depletion of endogenous
p62 by shRNA in both the MDA-MB-231 and the SUM149
cells (Figure 2B(a) and Supplementary Figure 1C). Moreover, the
sphere formation efﬁciency was dramatically reduced upon p62
depletion, as indicated by a decrease in both spheroid numbers
and diameters (Figure 2C(a) and Supplementary Figure 1D).
Conversely, both the colony number and the sphere formation
ability were enhanced by p62 overexpression in MCF-7 cells
(Figures 2B(b) and 2C(b)). Interestingly, the ALDH1+ population
was markedly decreased following the depletion of p62 and
increased by p62 overexpression in MDA-MB-231 cells (Figures 2D(a)
and (b)). In addition, we also conducted shRNA-mediated p62
knockdown in MDA-MB-231 cells and lentivirus-mediated p62
overexpression in MCF-7 cells for both RT-qPCR and western blot
analysis. As shown in Supplementary Figure 3, p62 knockdown
reduced both the mRNA and the protein levels of NANOG, SOX2
and POU5F1 (OCT4), whereas p62 upregulation promoted the
expression of these stemness markers. Together, these data implied
that p62 is necessary for promoting breast cancer stem-like
properties in vitro.
Depletion of p62 abrogated the tumor-initiating frequencies and
growth rates of BCSC-derived tumor xenografts in vivo
Given that p62 suppression diminished BCSC properties in vitro,
we then examined whether p62 knockdown would affect the
tumor-initiating potential of breast cancer cells. To this end, we
generated MDA-MB-231-shp62-2 stable cells with good knock-
down efﬁciency (Figure 2A(a)). An equal number of p62 knock-
down MDA-MB-231 cells (1 × 106 cells per mouse) were
subcutaneously injected into 4- to 6-week-old BALB/C (nu/nu)
female nude mice (5 mice in each group, 2 sites for each mouse).
Tumor xenografts were then monitored every week after
inoculation. Mice were killed after 8 weeks and tumor formation
incidences were analyzed. As shown in Figure 3a, mice inoculated
with the shp62-2 cells had a lower tumor incidence (2/10) and
tumors derived from shp62-2 stable cells (referred as shp62-2#1)
also grew at a signiﬁcantly reduced rate compared with shNC cells
(referred as shNC#1, 7/10).
Next, limiting dilution assay was employed to evaluate whether
depletion of p62 would impair the tumor-forming abilities of
xenograft-derived tumor cells. Single cells were isolated from
shNC#1 and shp62-2#1 xenografts by enzyme digestion, respectively.
Then, equal amounts of cells (1 × 106, 1 × 105, 1 × 104 and 1×103)
were subcutaneously inoculated into four different sites in each
mouse (n=3) (Figure 3b) and monitored for 8 weeks. Notably,
shNC cells (referred as shNC#2) formed tumors effectively at the
dilutions of 1×106, 1 × 105 and 1×104 (100%), with a relatively
lower incidence (66.7%, 2/3 sites) at the dilution of 1×103. The
tumor formation frequencies of shp62-2 cells (referred as shp62-2#2)
at each dilution (1×106, 1 × 105, 1 × 104 and 1×103) within the
same time frame were 100, 33.3, 0 and 0%, respectively (Figure 3c).
These results demonstrated that compared with control cells,
depletion of p62 gave rise to secondary tumor xenografts with
decreased frequencies, along with reduced tumor volumes.
Meanwhile, H&E morphological detection showed enhanced
accumulation of ﬁbroblastic tissues and massive neovasculariza-
tion in shNC#2 tumors but not in shp62-2#2 tumors (Figure 3d).
Immunohistochemistry (IHC) analysis of shNC#2 tumors revealed
abundant p62 protein resided within the cytoplasm and only
occasionally in the nucleus, along with massive Ki67-positive
staining (62.5 ± 12.5%) (Figure 3d and Supplementary Figure 4).
In contrast, suppression of p62 resulted in a dramatic reduction
in Ki67-positive staining in the shp62-2#2 tumors (6.0 ± 1.0%)
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(Figure 3d and Supplementary Figure 4). In addition, single
cells extracted from secondary tumor xenografts were subjected
to mammosphere formation assay to assess for their self-renewal
abilities. As shown in Figure 3e, both ﬁrst and second generation
of shp62 cells (isolated from shp62-2#2 xenografts) displayed
impaired mammosphere-forming efﬁciencies, as indicated by their
signiﬁcantly decreased spheroid numbers and diameters.
To further conﬁrm that inhibition of p62 in stem-cell
subpopulation can suppress tumor-initiating ability, we ﬁrst
performed ALDH1 sorting assay by using MDA-MB-231-shNC
and shp62 stably transfected cells before injecting into NOD/SCID
mice for xenograft tumor experiments (Supplementary Figure 5a).
The ALDH1+ cells in shp62 group exhibited lower p62 mRNA
expression level than in shNC group, along with lower expression
of NANOG, SOX2 and POU5F1 (Supplementary Figure 5b).
Then, two group with equal amounts of ALDH1+ cells (5 × 104)
were subcutaneously injected into NOD/SCID mice (n= 6). Mice
were killed after 6 weeks and tumor-initiating frequencies were
Figure 1. Expression of p62 is elevated in BCSC-enriched populations. (A) (a) Heat map displayed the expression signature of candidate genes
using genome mRNA expression proﬁling data (GSE15192) from GEO database. (b) Column graph represented the comparison of p62
expression values between CD44+/CD24− and CD44−/CD24+ subpopulations of MCF-10A cells. ***Po0.001, two-tailed Student’s t-tests.
BCSC-enriched populations were enriched for sphere formation assay (B), ALDH1-positive sorting assay (C) and side population assay (D),
respectively. Expression of candidate genes (p62, SOX2, NANOG, POU5F1) and their related proteins were analyzed by RT-qPCR and western
blot, respectively. **Po0.01, ***Po0.001, two-tailed Student’s t-tests. Error bars represented mean± s.d.
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Figure 2. p62 is essential for breast cancer cells to maintain stem-like properties in vitro. (A) Efﬁciencies for knockdown or overexpression
of p62 were tested by western blot analysis. (B) Comparison of plate colony formation numbers and (C) mammosphere-forming abilities
and ALDH1-positive populations (D) were analyzed following p62 interference. *Po0.05, **Po0.01, ***Po0.001. Error bars represented
mean± s.d. Scale bars, 100 μm.
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Figure 3. Suppression of p62 impairs the tumor-initiating ability of breast cancer cells in vivo. (a) Immunodeﬁcient mice (n= 5, 2 sites per
mouse) were subcutaneously inoculated with equal number of single cells (1 × 106 cells per mouse). Tumor xenografts were monitored for
8 weeks. Tumor volumes were monitored as described in Materials and methods. (b) Limiting diluted numbers of isolated tumor cells
were subcutaneously inoculated into immunodeﬁcient mice (n= 3) at the indicated sites. (c) Serial transplantation frequencies were analyzed
after 8 weeks. (d) H&E and IHC staining of xenografted tumor tissues. Scale bars, 100 μm. (e) Isolated single tumor cells from tumor xenografts
were subjected to sphere formation assay. Both ﬁrst and second mammosphere-forming abilities were compared. **Po0.01, ***Po0.001.
Error bars represented mean± s.d. Scale bars, 100 μm.
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Figure 4. High p62 expression levels indicate poor clinical outcome in breast cancer patients. (A) Ten pairs of breast tumors (T) and adjacent normal
tissues (N) were subjected to western blot analysis. Fold of p62 expression was normalized to adjacent normal tissue in each pair. (B) Representative
images of negative, low and high levels of p62 staining, which showed no, few and much visible cellular brown-yellowish granules, respectively
(a–c, ×100). The indicated ﬁelds of (a–c) are magniﬁed to show the clear staining granules (a’–c’, ×200). (C) Cumulative survival probabilities (a, OS and
b, DFS) were calculated through the Kaplan–Meier method (n=369) based on p62 expression. Survival rates were compared by log-rank test.
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analyzed. As shown in Supplementary Figure 5c and d, compared
with shNC group (6/6), mice inoculated with the shp62 cells
exhibited a lower tumor incidence (5/6), along with reduced
tumor volumes. Collectively, these data showed that depletion of
p62 abrogated the tumor-initiating efﬁciency and growth of
BCSC-derived tumor xenografts in vivo, supporting a critical role of
p62 in the promotion of breast cancer stem-like properties.
High p62 expression is associated with poorer prognosis in breast
cancer
To evaluate the clinical relevance of p62-mediated stem-like
properties, we ﬁrst collected 10 pairs of breast cancer and
adjacent normal tissues, and conducted western blot analysis of
p62 expression levels. The results showed that all breast cancer
tissues displayed higher p62 expression levels at varying degrees
when compared with adjacent normal tissues (from 1.09-fold to
4.28-fold, normalized to Actin) (Figure 4A). In addition, we also
examined the p62 expression in a total of 369 breast cancer
patients. (The median age is 48 years old.) IHC staining was
executed to evaluate the p62 protein expression levels. Compared
with normal breast tissues (employed as a negative control),
the p62 protein expression was signiﬁcantly higher in breast
cancer tissues. (Representative images were shown in Figure 4B.)
The relationship between p62 protein expression and clinicopatho-
logical parameters of breast cancer patients was summarized in
Table 1. High p62 protein expression was signiﬁcantly correlated
with clinical stage (P=0.011) and node stage (P=0.004). In
comparison, no signiﬁcant correlations were discovered between
p62 protein expression and other clinicopathological characteristics.
Moreover, the Kaplan–Meier survival analysis demonstrated that
high level of p62 was a strong indicator for an inferior OS and
DFS (Figure 4C, P-values were 0.000 and 0.001, respectively) in our
patient cohort, suggesting a signiﬁcantly unfavorable prognosis
and shorter life span. In multivariate analysis, p62 was also
a signiﬁcant predictor for poor OS (P= 0.000, Hazard ratio 4.669,
95% CI from 2.313 to 9.426, Table 2) and poor DFS (P= 0.014,
Hazard ratio 2.040, 95% CI from 1.156 to 3.602, Table 2). Thus,
these data suggested that p62 can be a potential independent
prognostic factor for breast cancer, with high p62 expression
associated with poor diagnosis and prognosis.
MYC is necessary for the maintenance of p62-mediated stem-like
properties in breast cancer
In an effort to investigate the downstream target for p62-
mediated stem-like properties in breast cancer, we extracted total
RNA from both shNC#2 and shp62-2#2 tumor xenografts,
generated the global gene expression proﬁle by using Affymetrix
Human Primeview (analyzed from independent triplicates)
(Figure 5a), and then compared the array data (41.5-fold)
with one stem-cell gene set.37 As shown in Figure 5b, a series of
stemness-associated genes showed declined expression levels in
shp62-2#2 tumor xenografts, including the MYC gene (−4.389-fold),
which was recently revealed to be a key factor in breast cancer
stemness.38–40 We thus hypothesized that MYC might act as
a downstream target for p62-mediated breast cancer stem-like
properties. To test this conjecture, we ﬁrst validated the array data
by employing RT–PCR and western blot analysis. The results
conﬁrmed that MYC expression was robustly inhibited following
suppression of p62 (Figure 5c). Meanwhile, considering that c-Myc
protein, encoded by the MYC gene, is a multifunctional transcrip-
tion factor that regulates transcription of various target genes, we
performed the gene set enrichment analysis (GSEA) of the
expression proﬁle and found that suppression of p62 signiﬁcantly
diminished the enrichment of genes that are regulated by c-Myc
(Figure 5d and Supplementary Figures 6a and b), indicating
a reduction in c-Myc transcriptional activity.
Table 2. Results of multivariate Cox proportional-hazards analysis for overall survival (OS) and disease-free survival (DFS) in breast cancer patients
(n= 369)
Variable For OS For DFS
Hazard ratio 95% Conﬁdence interval P Hazard ratio 95% Conﬁdence interval P
Age
o48.00 (vs ⩾ 48 years)
0.554 0.236–1.301 0.175 0.782 0.382–1.598 0.500
Tumor stage
T3+T4 (vs T1+T2)
1.413 0.667–2.995 0.367 1.037 0.500–2.148 0.923
Node stage
N2+N3 (vs N0+N1)
1.927 0.846–4.387 0.367 3.435 1.555–7.588 0.002
Clinical stage
III+IV (vs I+II)
2.391 1.123–5.091 0.024 1.762 0.928–3.348 0.083
p62
High (vs Low)
4.669 2.313–9.426 0.000 2.040 1.156–3.602 0.014
Table 1. Association of p62 expression with clinicopathological
characteristics in breast cancer patients (n= 369)
Variable All cases, N (%) p62 expression Pa
Low High
Age (years) 0.614
o48 173 (46.9) 89 84
⩾ 48b 196 (53.1) 106 90
Clinical stage 0.011
I 76 (20.6) 46 30
II 173 (46.9) 96 77
III 117 (31.7) 52 65
IV 2 (0.5) 0 2
Missing cases 1 (0.3)
T stage 0.700
T1 126 (34.1) 69 57
T2 192 (52.0) 101 91
T3 25 (6.8) 10 15
T4 25 (6.8) 14 10
Missing cases 1 (0.3)
Node stage 0.004
N0 167 (45.3) 102 65
N1 98 (26.6) 49 49
N2 71 (19.2) 28 43
N3 32 (8.6) 15 17
Missing cases 1 (0.3)
ax2 test. bMedian age.
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As a result, we examined the correlation between p62 and MYC in
breast cancer cell lines in vitro. Two different RNAi sequences of p62
were applied to transiently knockdown p62 in MDA-MB-231, BT-549
and SKBR-3 breast carcinoma cells. Seventy-two hours after
transfection, RT-qPCR (three pairs of primers designed for MYC)
and western blot assays were conducted to evaluate the mRNA and
protein levels of MYC. As shown in Figure 6A, both RNAi sequences
of p62 decreased the MYC mRNA and protein levels in the three cell
lines. Conversely, overexpression of p62 in MDA-MB-231 and MCF-7
cell lines enhanced both the mRNA and protein levels of MYC
(Figure 6B). These results conﬁrmed that p62 is positively correlated
with MYC mRNA levels in breast cancer cells.
We previously reported that epirubicin-resistant MCF-7
(EpiR-MCF-7) cells displayed abundant stem-like properties
compared with their wild-type counterparts (WT-MCF-7).21 In this
study, we found that EpiR-MCF-7 cells exhibited enhanced
mammosphere-forming capacity (Figures 6D(a) and (c)). Impor-
tantly, we observed that both p62 and MYC were elevated at the
mRNA and protein levels in EpiR-MCF-7 cells (Figures 6C(a) and
(b)). Both shRNA-mediated knockdown of p62 caused a reduction
in MYC expression in EpiR-MCF-7 cells (Figure 6C(b)), as well as a
decreased ability to form mammospheres (Figures 6D(c) and (e)).
To further conﬁrm a role of MYC for the p62-mediated stem-like
properties in breast cancer, we conducted lentivirus-mediated MYC
ectopic overexpression in both WT-MCF-7 and EpiR-MCF-7 cells. In
accordance with previous studies, overexpression of MYC resulted
in a signiﬁcant increase in the mammosphere-forming ability in
WT-MCF-7 cells (Figure 6D(b)). Critically, re-constitution of MYC
expression in EpiR-MCF-7-shp62-2 cells abolished the reduced
mammosphere-forming ability (Figure 6D(f)). In addition, we
conducted shRNA-mediated MYC suppression in both MCF-7-Ctrl
and MCF-7-p62-OE cells. Notably, overexpression of p62 caused an
increment in MYC expression in MCF-7 cells, along with an increased
ability to form mammospheres (Figures 6E, 6F(a) and (c)).
Furthermore, knockdown of MYC in MCF-7-p62-OE cells attenuated
the increased mammosphere-forming ability (Figure 6F(d)). Taken
together, these results indicated that MYC is necessary for the p62-
promoted stem-like properties in breast cancer.
p62 promotes MYC mRNA stability at the post-transcriptional level,
rather than inﬂuencing its promoter activity
To investigate the molecular mechanism whereby p62 regulates
the MYC mRNA level, we ﬁrst examined whether p62 can directly
Figure 5. p62 is positively correlated with MYC expression level in xenografted tumor tissues. (a) An unbiased genome mRNA expression
proﬁling heat map between shNC#2 and shp62-2#2 xenografted tumor tissues (analyzed from three independent tests). (b) Comparison of
array data (41.5-fold) with one stem gene set. Common genes were listed in the column graph according to their fold changes. (c) Validation
of MYC gene expression by RT–PCR and western blot analysis in the paired xenografted tissues. (d) GSEA of MYC downstream target genes
(false discovery rate (FDR)⩽ 0.25 and Po0.05 were considered signiﬁcant).
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Figure 6. MYC acts as a functional effector for p62-mediated breast cancer stem-like properties. Validations of MYC mRNA and protein levels were
examined following p62 transient knockdown (A) or overexpression (B). Transient knockdown was mediated by two different RNAi sequences
(si#1, si#2). MYC mRNA abundance was detected by three different primers (MYC#1, #2, #3). Heat map displayed MYC mRNA levels from three
independent RT-qPCR tests. MYC expression levels (c-Myc) were assessed by western blot and normalized to Actin. (C) Both p62 and MYC
expression levels were measured by RT–PCR (a) and western blot (b) assays in wild-type MCF-7 (WT) and epirubicin-resistant MCF-7 (Epi) cells.
Efﬁciencies of shRNA-mediated suppression of p62 were examined by western blot analysis (b). (D) Mammosphere-forming abilities were compared.
***Po0.001. Scale bars, 50 μm. (E) shRNA-mediated MYC suppression in both MCF-7-Ctrl and MCF-7-p62-OE cells. p62 and MYC expression levels
were assessed by western blot. And mammosphere-forming abilities were compared. **Po0.01; ***Po0.001. Scale bars, 100 μm, (F).
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regulate MYC transcription. To this end, we cloned the full
sequence of MYC promoter (Figure 7A(a)) by PCR and inserted into
luciferase reporter pGL3-basic plasmid through Mlu I and
Hind III cloning sites. Dual-luciferase reporter results showed
that luciferase ﬁreﬂy did not signiﬁcantly change after p62
overexpression in both MDA-MB-231 (Figure 7A(b)) and MCF-7
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cells (Supplementary Figure 7), suggesting that p62 does not
inﬂuence the proximal MYC promoter activity.
We next asked whether p62 would affect MYC mRNA stability
after transcription. We overexpressed p62 in MDA-MB-231 and
MCF-7 cells, and then treated cells with Actinomycin D (ActD)
to block de novo mRNA synthesis and total RNA was isolated at
indicated time points (0, 30, 60 and 90min) after ActD application.
Relative MYC mRNA levels were measured by quantitative RT–PCR
normalized to that at 0 min (using Actin as the internal control).
As shown in Figure 7B, p62 was overexpressed in MDA-MB-231 cells,
and that extended the half-life of MYC mRNA. T1/2 for the vector
counterpart (Ctrl) and p62-WT in MDA-MB-231 cells was 38.68 and
70.88 min, respectively. Similar results were obtained in MCF-7 cells
(Supplementary Figure 8). Taken together, these results suggest that
p62 specially increases MYC mRNA stability after transcription, thus
elevating its expression level.
Previous studies have reported that the let-7 cluster can bind to
the consensus binding sites in the 3’untranslated region (UTR) of
MYC mRNA transcript, leading to its degradation via the RNA
miRNA-induced silencing complex.41–45 To test whether p62
regulates MYC expression via let-7 cluster, total RNA was extracted
from MDA-MB-231 cells with or without transient p62 over-
expression. RT-qPCR analysis of the let-7 cluster in the
transfected cells showed that let-7a/b were signiﬁcantly
repressed by p62 overexpression (Figure 7C). Indeed, consistent
with previous reports, transfection of let-7a/b mimics sup-
pressed MYC expression in both MDA-MB-231 and MCF-7 cell
lines (Supplementary Figure 9; Dicer protein level was detected
to assess the efﬁciencies of the mimics). To determine whether
the reduced expression of let-7a/b was responsible for p62-
mediated stabilization of MYC mRNA, we co-transfected let-7a/b
mimics with p62 in breast cancer cells. The results showed that
re-constitution of let-7a/b activity by the mimics reversed the
p62-mediated elevation of MYC at the mRNA and protein levels
(Figures 7D(a) and (b)). Taken together, these results suggest
that the microRNA let-7a/b have a critical role in the regulation
of MYC mRNA stability and expression by p62.
DISCUSSION
In the present study, we uncover a previously unrecognized role of
p62 in the regulation of breast cancer stem-like properties based
on the following novel ﬁndings: (a) p62 expression is elevated
in BCSC-enriched cell populations (Figure 1); (b) p62 is essential
for promoting breast cancer stem-like properties both in vivo
and in vitro (Figures 2 and 3, Supplementary Figure 5); (c) p62 is
overexpressed in breast cancer tissues, and high p62 expression
levels predict poorer clinical outcome (Figure 4); (d) p62 specially
promotes MYC mRNA stability, mostly by repressing the expres-
sion of let-7a /b (Figures 5–7).
Given its contributions to tumor relapse and drug resistance,
the BCSC population is considered as a key therapeutic target for
breast cancer treatments. However, due to the heterogeneity
and dynamic status of the BCSCs, there are hitherto no available
strategies to eliminate BCSCs effectively. Thus, the elucidation
of key molecules and mechanisms underlying BCSC regulation
is urgently needed. We report here for the ﬁrst time that
BCSC-enriched populations (CD44+/CD24− subpopulation, mam-
mospheres, ALDH1+ populations and SP cells) display high levels
of p62 expression (Figure 1). Further analysis conﬁrmed that
p62 is required for self-renewal and tumor-initiating abilities of
BCSCs (Figures 2 and 3, Supplementary Figure 5). Notably, at
least 1 × 105 shp62 MDA-MB-231 cells were required to get 33%
tumor graft rate (1/3 sites), whereas as few as 1 × 103 shNC
MDA-MB-231 cells could robustly initiate tumors (2/3 sites)
within the same time frame. Previous reports point out that p62
is partially involved within cisplatin resistance in human ovarian
cancer cells, possibly by modulating Keap1-NRF2-ARE signaling
activities.46 Indeed, our results also revealed that suppression
of p62 reduced the mammosphere-forming ability of the
epirubicin-resistant MCF-7 cells (Figure 6D), a cell line that
shows aggressive stem-like features and multidrug resistance.21
Collectively, our data strongly suggest p62 as a potential target
to limit breast cancer stemness, thus overcoming BCSC-
mediated drug resistance.
p62 has been recently reported to exert a role in controlling
mitosis transition through CDK1-mediated phosphorylation at
Threonine 269 (T269) and Serine 272 (S272).47 p62 can bind to
and inhibit Twist-1 autophagic degradation, thus promoting
xenografted human skin cancer cell growth in a Twist-dependent
manner.48 In our study, we performed BrdU, cell-cycle and
apoptosis assays to investigate whether the effects of p62 arisen
from its inﬂuence on cell short-term proliferation and viability.
The results showed that there were no signiﬁcant differences in
the number of BrdU-positive cells in both the p62 knockdown
MDA-MB-231 cells and the p62 overexpression MCF-7 cells when
compared with their control counterparts (Supplementary Figure
11A(a) and (b)). In addition, cell-cycle assays indicated that there
were no changes in G0/G1, S and G2/M phase cells following the
depletion or overexpression of p62 (Supplementary Figure 11B(a)
and (b)). Together with the results shown in Supplementary
Figure 10, which indicate that neither forced expression nor
depletion of p62 impaired the growth rate of breast cancer cells in
a short time frame, as indicated by proliferative assays of up
to 4th–6th day, suggesting that p62 is not capable of inﬂuencing
the short-term proliferative ability of breast cancer cells. Con-
sistent with our ﬁndings, one recent study has shown that cell
growth rates are not altered till the 4th day by shRNA-mediated
suppression of p62 in mouse embryo ﬁbroblasts.49 Moreover,
apoptosis detection by Annexin-V/PI using ﬂow cytometry showed
no changes following p62 depletion or overexpression in breast
cancer cells (Supplementary Figure 12). Therefore, these ﬁndings
led us to conclude that the reduced spheroid formation
and tumor-initiating abilities caused by p62 knockdown were
independent of the function of p62 to induce cell proliferation and
survival in breast cancer. In longer term experiments, suppression
of p62 decreased colony-forming abilities (Figure 2B and
Supplementary Figure 1C), as well as reduced Ki67-positive rate
Figure 7. p62 promotes MYC mRNA stability after transcription. (A) Full length of MYC promoter sequence was cloned and inserted into
pGL3-Basic plasmid (a), and dual-luciferase assay was performed in MDA-MB-231 cells as described in Supplementary Materials and Methods
(b). Transcription activity was calculated as the ratio of Fireﬂy luciferase activity (reporter) vs Renilla luciferase activity (control). Error bars
represented mean± s.d. Comparison was analyzed by two-tailed Student’s t-tests. (B) MDA-MB-231 cells were transiently transfected with
wild-type (WT) p62 construct for 48 h. Actinomycin D (ActD, 5 μg/ml) was added for indicated time points (0, 30, 60 and 90 min) before
harvest. MYC mRNA levels were assessed by RT-qPCR analysis. (a) Transfection efﬁciencies of p62 were determined by RT–PCR analysis.
(b) Relative fold of expression was calculated by normalizing mRNA level to that at 0 min (without ActD treatment) for both control (Ctrl) and
p62-overexpressed (p62-WT) groups. Results were representative of three independent experiments. Error bars represented mean± s.d.
(c) Half-life of mRNA for each group was predicted according to fold described in (b). (C) Expression of the let-7 cluster was analyzed by
RT-qPCR assay (RNU6-2 was used as an internal control). Error bars represented mean± s.d. Comparison was analyzed by two-tailed Student’s
t-tests. **Po0.01, ***Po0.001; n.s., not signiﬁcant. (D) The let-7a/b activities were reconstituted by mimics. Relative mRNA abundance of MYC
was examined by RT-qPCR assay, and c-Myc protein level tested by western blot. Error bars represented mean± s.d.
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in tumor xenografts (Supplementary Figure 4). One possible
explanation for the apparent contradiction might be the diverse
culture conditions. Plate colony formation reﬂected the ability of
one single cell to self-renewal over long periods of time (~14 days),
while tumor cell transplantation studies reveal stem-like proper-
ties (at least 28 days).
Recent studies suggest that autophagy has a crucial role in the
origin, maintenance and systemic distribution of BCSCs.50 Here, we
examined the markers of autophagy following p62 depletion or
overexpression in breast cancer cells. Surprisingly, LC3 conversion was
not signiﬁcantly changed by either knockdown or overexpression of
p62, indicating that p62 does not alter autophagic activities under
normal culture conditions (Supplementary Figure 13A). In addition, we
labeled the single cells, which were isolated from the third generation
of spheroids from shNC and shp62 groups, with an autophagic
vacuole dye, monodansylcadaverine. As shown in Supplementary
Figure 13B, there were no signiﬁcant differences in the number of
autophagic vacuoles formed in shNC and shp62 cells, indicating
that p62-mediated mammosphere-forming capacity is not primarily
regulated by autophagy. To further assess whether autophagy has
a role in regulating the p62-mediated stem-like properties in breast
cancer, we conducted shBeclin1-mediated knockdown of autophagy
in both MDA-MB-231-shNC and shp62 cells. Inhibition of auto-
phagy resulted in a signiﬁcant increase in the mammosphere-forming
capacity in MDA-MB-231-shNC cells (Supplementary Figure 14).
Critically, suppression of autophagy in MDA-MB-231-shp62 cells
could not reverse the reduction in mammosphere-forming ability
induced by p62 depletion (Supplementary Figure 14), suggesting that
autophagy is unlikely to have a key role in mediating the p62-induced
stem-like properties in breast cancer. However, we cannot absolutely
rule out the possibility that autophagy is not involved in modulating
the p62-mediated breast cancer stem-like properties, due to the
dynamic nature of BCSCs and microenvironmental stresses.50
In an effort to investigate the mechanisms underlying the
regulation of MYC expression by p62, we found that p62 enhances
MYC mRNA expression at the post-transcriptional level rather than
through promoting its transcriptional activity (Figure 7). MYC mRNA
stabilization is mainly determined by two intrinsic instability
elements, localizing in the 5’ and 3’ UTR, respectively. The 5’UTR
element is composed of 249 nucleotides, also termed as coding
region determinant, which can be recognized by endonucleases,
thus promoting MYC mRNA degradation. Several proteins have
been assigned to stabilize MYC mRNA by speciﬁcally recognizing
and binding to the CRD, thus preventing endonucleolytic cleavage
of MYC mRNA, such as the Coding Region Determinant-Binding
Protein,51–53 and IGF2BP1.54 The 3’UTR instability element is rich in
adenine and uracil (AURE, AU-rich element). Both HUR and let-7
have been reported to bind to the 3’-element, thus destabilizing
MYC mRNA level and repressing its expression.55,56 In our study, we
found that forced p62 expression signiﬁcantly delayed half-life of
MYC mRNA in breast cancer cell lines (Figure 7B and Supplementary
Figure 8), indicating a role of p62 in stabilizing MYC mRNA.
However, we failed to detect a direct binding of p62 with MYC
mRNA (Supplementary Figure 15), ruling out the possibility that p62
acted as an RNA-binding protein to stabilize MYC mRNA directly.
Intriguingly, we uncover here that let-7a and let-7b act as a key
effector in the regulation of MYC mRNA stability by p62 (Figures 7C
and D). Let-7 is a conserved microRNA family, which can function as
a tumor suppressor.44,45,57 Our data suggested a negative feedback
correlation between p62 and the let-7 microRNA family (Figure 7C),
further conﬁrming the oncogenic role of p62 in breast cancer.
Nevertheless, the exact mechanism accounting for the p62-
mediated repression of let-7a and let-7b requires further evaluation.
Meanwhile, given that p62 can activate mTORC1 signaling in
response to amino-acid stimuli,26 and c-Myc has been found to
be a key transcription factor regulated by mTORC1 signaling,58 we
also tested the role of mTORC1 signaling in p62-mediated
stabilization of MYC mRNA. Although rapamycin (a small-molecule
inhibitor of mTORC1 kinase) effectively inhibited MYC expression
(Supplementary Figure 16a), it did not block the elevation of c-Myc
protein by p62 overexpression (Supplementary Figure 16b), sug-
gesting that mTORC1 signaling is not likely to be involved in the
regulation of MYC mRNA stability by p62 in our system.
In summary, we demonstrate that the signaling adaptor
p62-promoted breast cancer stem-like properties through stabiliz-
ing MYC mRNA at the post-transcriptional level. Our ﬁndings also
suggest that target p62 might be a promising avenue for
therapeutic intervention for overcoming BCSC-mediated drug
resistance and tumor relapse.
MATERIALS AND METHODS
Cell culture
The human breast cancer cell lines (MDA-MB-231, BT-549, MCF-7 and
SKBR-3), the immortalized human breast epithelial cell line MCF-10A and
human embryonic kidney HEK293T cell line were obtained from the
American Type Culture Collection (ATCC). The epirubicin-resistant MCF-7 cells
(EpiR-MCF-7) have previously been described.59 The SUM149 cell line was
kindly provided by Prof. Zhi-Min Shao (Department of Medical Oncology,
Cancer Hospital of Fudan University, Shanghai Medical College, Shanghai,
China). Cell lines were acquired from the Cell Culture Service, Cancer
Research UK, where it was tested and authenticated, and were not cultured
continuously for more than 3 months. Each cell line was cultured in its
standard medium as recommended by ATCC. SUM149 cells were cultured in
F-12 Hams (Gibco, New York, NY, USA) supplemented with 5% FBS (Hyclone,
Logan, UT, USA), 5 μg/ml insulin (Sigma-Aldrich, St Louis, MO, USA) and 1 μg/ml
hydrocortisone.
Patients and follow-up, tissue microarray and IHC assay
This study comprises 369 female breast cancer patients diagnosed between
August 1999 and October 2008 at Sun Yat-sen University Cancer Center. All
patients were staged according to the American Joint Committee on Cancer
(AJCC) TNM staging system for breast cancer (seventh edition). Tissue
microarray sections were constructed, and immunohistochemical analysis
was performed as previously described.60 Detailed information is described
in Supplementary Materials and Methods.
RNAi and microRNA transfection
Transient RNAi transfection was carried out as previously described.61 Two
different target siRNA sequences of p62 were obtained from GenePharma
Co., Ltd (Shanghai, China) (1#, 5′-GUGACGAGGAAUUGACAAUTT; 2#, 5′-GG
AGUCGGAUAACUGUUCATT). The negative control siRNA was 5′-UUCU
CCGAACGUGUCACGUTT. The let-7a mimic (5′-UGAGGUAGUAGGUUGU
AUAGUU; 5′-CUAUACAACCUACUACCUCAUU) and the let-7a mimic
(5′-UGAGGUAGUAGGUUGUGUGGUU; 5′-CCACACAACCUACUACCUCAUU)
were obtained from Invitrogen and transfected into the culture cells using
Lipofectamine2000 Transfection Reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions.
Plasmid construction
Full length of p62 fragment was cloned from human genome cDNA and
ligated into pCDH vector (System Biosciences, Palo Alto, CA, USA). The
primers were as follows: p62: 5’ XbaI, 5′-GCTCTAGAGCGCCACCATGG
CGTCGCTCACCGTGAAGGCC; 3′ EcoRI, 5′-CCGGAATTCCGTCACAACGGCGGG
GGATGCTTTGA. The MYC promoter fragment was cloned from human
genomic DNA and ligated into the pGL3-basic vector (Promega, Madison,
WI, USA) upstream of the luciferase reporter. Primers were as follows:
5′ MluI, 5′-CGACGCGTCGGCCACCGGGAGAGAAAAGTTTACT; 3′ HindIII,
5′-CCCAAGCTTGGGCTGGTTTTCCACTACCCG. The full-length MYC plasmid
was kindly provided by Dr Fei-Meng Zheng (State Key Laboratory of
Oncology in South China, Cancer Center, Sun Yat-sen University,
Guangzhou, China) and packaged for lentivirus particles. The shRNA
targeting p62 (1#, 2#) and the non-target shRNA (SHC002) were kindly
provided Dr Zi-Jie Long (Department of Hematology, the Third Afﬁliated
Hospital, Sun Yat-sen University, Guangzhou, China) and packaged for
lentivirus particles. Lentiviral particles containing shBeclin1 (131209AZ)
and LV3 (131127CZ) control expression vectors were purchased from
Shanghai GenePharma Co., Ltd. For lentivirus preparation, see
Supplementary Materials and Methods.
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Gene expression proﬁling analysis and Bioinformatics analysis
Total RNA was extracted from both shNC and shp62 groups of xenografted
tumor tissues using Trizol reagent and subjected to AFFYMETRIX Human
Primeview array (Gene Tech (Shanghai) Company Limited) to determine the
global expression of mRNA. Each group was tested in triplicate. GSEAs were
performed using GSEA v2.0.13 software (http://www.broad.mit.edu/gsea).62
The gene expression signatures were acquired from the GSEA website
(V$MYC_Q2, V$MYCMAX_B and V$MYCMAX_01). Statistical signiﬁcance was
evaluated by means of false discovery rate (⩽0.25) and P-value calculations
(Po0.05).
For Mammosphere formation assay, SP assay, Cell plate colony formation
assay, Animal studies, RNA extraction, Reverse transcription-PCR, Real-time
quantitative PCR, Dual-luciferase reporter assay, Western blot analysis, RNA
and protein immunoprecipitation and Statistical analysis, see Supplementary
Materials and Methods.
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